Schizophrenia

Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters

Retrieved on: 
Thursday, February 15, 2024

BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.

Key Points: 
  • BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.
  • In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist,” the authors describe the development of CVN766 to be over 1,000-fold more selective for the orexin 1 receptor (Ox1R) than the orexin 2 receptor (Ox2R).
  • Dysfunction of this target, Ox1R, is implicated in psychiatric disorders, such as schizophrenia, addictions (including food), and anxieties.
  • “CVN766 has demonstrated high brain permeability, prolonged receptor occupancy, and a pharmacokinetic and safety profile suitable for clinical evaluation across various psychiatric indications,” said Mark Carlton, Ph.D., chief scientific officer for Cerevance.

Royalty Pharma Reports Q4 and Full Year 2023 Results

Retrieved on: 
Thursday, February 15, 2024

In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.

Key Points: 
  • In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.
  • Royalty Pharma began repurchasing its Class A ordinary shares in April 2023 under a $1.0 billion multi-year share repurchase program.
  • During the fourth quarter of 2023, Royalty Pharma announced new transactions of up to $1.6 billion.
  • Royalty Pharma will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2023 results today at 8:00 a.m., Eastern Time.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

uMotif and MoCA Cognition Bring Modern, Patient-Centric eCOA/ePRO, MoCA Test and New XpressO Mobile App to Clinical Trials, Real-World Studies for CNS-Related Conditions

Retrieved on: 
Monday, February 12, 2024

BOSTON and LONDON, Feb. 12, 2024 /PRNewswire-PRWeb/ -- uMotif – one of the clinical research technology market's fastest-growing companies – and MoCA Cognition, creators of the leading test for early cognitive impairment detection – are collaborating to make it easier for sponsors and CROs to capture quality cognitive function and eCOA/ePRO data for CNS research.

Key Points: 
  • The company continues to deepen its portfolio across CNS through its partnership with MoCA Cognition, whose MoCA Test (Montreal Cognitive Assessment) was ranked No.
  • MoCA Cognition CEO and Neurologist Dr. Ziad Nasreddine created the MoCA Test in 1996 to help clinicians and researchers rapidly scan multiple cognitive domains and detect impairment.
  • The standard MoCA test is administered to patients, and can be uploaded into the uMotif platform for central rating and review.
  • Solutions using the standard MoCA test and the uMotif platform are available for immediate deployment.

This is how tobacco damages our cells

Retrieved on: 
Friday, February 9, 2024

With the countless studies available today on the effects of tobacco use, we should have no trouble convincing ourselves and others of how harmful it is.

Key Points: 
  • With the countless studies available today on the effects of tobacco use, we should have no trouble convincing ourselves and others of how harmful it is.
  • The cells that make up our tissues, organs and body systems are sensitive to the effects of external toxic agents, many of which can be found in tobacco.
  • Many smokers not only accept this, but also ignore the serious danger it poses to the people around them.

Initial effects in the mouth and pharynx

  • When tobacco smoke enters our body, the first cells to receive it are in the mouth, nose and throat.
  • These effects on the immune system are also linked to a higher likelihood of developing cancer.
  • We also cannot forget that tobacco smoke robs us of our sense of taste and smell, leaving an almost continuous bitter taste in the mouth.

Lung damage

  • Furthermore, due to the direct damage caused by tobacco on the tissue that maintains the structure of the lungs, the bronchi and bronchioles become blocked, generating symptoms similar to suffocation.
  • As if that were not enough, people with COPD are also more likely to develop cardiovascular disease, and lung cancer.

Black tar and macrophages

  • We can cast our minds back to the previous image of my father’s pipe, black and sticky with tar.
  • It so happens that the lungs are rich in macrophages – special cells that play a key role in our immune systems by reacting to attacks, producing inflammatory responses.
  • These cells end up ingesting the tar from tobacco, and they eventually die loaded with this substance which builds up and gives a smoker’s lungs their characteristic blackened appearance.

Nicotine’s effects on neurons: dependence and addiction

  • As with any other compound that stimulates neurotransmitter receptors, permanent stimulation desensitises neurons.
  • This means that the neurons reduce the number of receptors, or change their sensitivity to the stimulant.
  • This desensitisation process can lead not only to nicotine dependence, but also to other diseases such as memory loss.


Guillermo López Lluch is a member of the Spanish Society of Cell Biology, the Spanish Society of Biochemistry and Molecular Biology, the Spanish Society of Geriatrics and Gerontology, the Society for Free Radical Research and the International Coenzyme Q10 Association. The research carried out by the author is financed by public funds from the Spanish Government or the Autonomous Government of Andalusia.

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip

Retrieved on: 
Friday, February 9, 2024

The fireside chat will delve into the early findings from BullFrog AI and LIBD’s collaboration which successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.

Key Points: 
  • The fireside chat will delve into the early findings from BullFrog AI and LIBD’s collaboration which successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.
  • For the first time, this partnership has enabled the clustering of subjects based on biological data alone, independent of their behavioral diagnoses.
  • This innovative method has uncovered biological differences and similarities across various brain disorders and has identified potential biological subtypes within individual disorders.
  • To participate in the fireside chat, please register at:

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Retrieved on: 
Thursday, February 8, 2024

COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.

Key Points: 
  • The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology.
  • COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.
  • Through rigorous research and development efforts, Tetra Pharm Technologies has unlocked the potential of this biological system to address one of the most pressing health challenges of our time – excessive appetite and weight gain.
  • By specifically targeting the endocannabinoid system, Tetra Pharm Technologies' solution holds promise for combating obesity and related metabolic disorders, with far-reaching implications for public health.

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Retrieved on: 
Thursday, February 8, 2024

COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.

Key Points: 
  • The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology.
  • COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.
  • Through rigorous research and development efforts, Tetra Pharm Technologies has unlocked the potential of this biological system to address one of the most pressing health challenges of our time – excessive appetite and weight gain.
  • By specifically targeting the endocannabinoid system, Tetra Pharm Technologies' solution holds promise for combating obesity and related metabolic disorders, with far-reaching implications for public health.

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Retrieved on: 
Tuesday, February 6, 2024

CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event on Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP (Retired professor of Psychiatry, Pharmacology and Psychiatry, The University of Texas; Chief Scientific Officer, Owner, Follow the Molecule LLC) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute), who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine (RP5063), a next-generation serotonin/dopamine modulator, as a potential treatment.

Key Points: 
  • CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event on Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP (Retired professor of Psychiatry, Pharmacology and Psychiatry, The University of Texas; Chief Scientific Officer, Owner, Follow the Molecule LLC) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute), who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine (RP5063), a next-generation serotonin/dopamine modulator, as a potential treatment.
  • To register, click here .
  • The event will focus on reviewing Reviva's positive topline results and successful completion of pivotal Phase 3 RECOVER trial evaluating the efficacy, safety, and tolerability of once-daily brilaroxazine in adults with acute schizophrenia, as well as the Company's ongoing enrollment in the one-year open label extension (OLE) trial and the initiation of registrational Phase 3 RECOVER-2 trial.
  • A live question and answer session will follow the formal presentations.

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

Retrieved on: 
Monday, February 5, 2024

NEW HAVEN, Conn., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the United States Patent and Trademark Office (“USPTO”) has allowed U.S. Patent Application No. 17/496,470 with claims pertaining to a method of treating agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form. The broad claims encompass film formulations such as BXCL501 (sublingual dexmedetomidine), tablets, or wafers. The patent, when issued, is expected to have an expiration date of Dec. 29, 2037, subject to patent term adjustment (“PTA”), patent term extension (“PTE”), and terminal disclaimers.

Key Points: 
  • 17/496,470 with claims pertaining to a method of treating agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form.
  • The broad claims encompass film formulations such as BXCL501 (sublingual dexmedetomidine), tablets, or wafers.
  • The patent, when issued, is expected to have an expiration date of Dec. 29, 2037, subject to patent term adjustment (“PTA”), patent term extension (“PTE”), and terminal disclaimers.
  • The Company also announced that it has received an issue notification from the USPTO for U.S. Patent Application No.